as we can see that in the opening, pharma space is showing strength and Biocon is holding bullish momentum after recent positive turnaround in earnings and improving financial performance, where company posted strong profit growth and got upgraded outlook
Technically, stock is trading above key EMAs indicating strength, MACD is in bullish crossover and momentum is building, while RSI is near 60–65 zone showing upside room without being overbought